Thursday, November 29, 2018 1:40:40 PM
The meeting is scheduled for January 8th, 2019 for shareholders of record as of November 23, 2018. Meeting materials will be distributed shortly after the record date in accordance with the Notice-and-Access provisions of National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer.
Trading in the shares of Portage is expected to resume on CSE shortly after the meeting materials have been posted.
Neither CSE nor its Market Regulator (as the term is defined in the policies of CSE) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward looking statements concerning future operations of Portage Biotech Inc. (the "Company"). All forward looking statements concerning the Company's future plans and operations, including management's assessment of the Company's expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company's control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and financial results may differ materially from any estimates and projections.
Cision View original content:http://www.prnewswire.com/news-releases/portage-announces-setting-of-meeting-date-to-approve-salvarx-acquisition-300754058.html
SOURCE Portage Biotech Inc.
Recent PRTG News
- Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives • GlobeNewswire Inc. • 04/12/2024 12:01:00 PM
- Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares • GlobeNewswire Inc. • 03/26/2024 12:01:13 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/08/2024 10:30:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 10:04:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/28/2024 10:19:51 PM
- Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update • GlobeNewswire Inc. • 02/28/2024 10:10:19 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:50:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/18/2024 10:09:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/04/2024 01:10:06 PM
- Portage Biotech Reports Business and Strategic Update • GlobeNewswire Inc. • 01/04/2024 01:00:37 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/01/2023 09:05:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/28/2023 09:03:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 09:02:08 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/28/2023 09:01:24 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/14/2023 11:00:29 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 11:10:09 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/08/2023 05:15:28 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/07/2023 09:50:10 PM
- Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting • GlobeNewswire Inc. • 11/06/2023 01:01:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 10/31/2023 08:05:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/29/2023 12:01:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/08/2023 08:01:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2023 12:00:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2023 08:01:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2023 08:52:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM